The purpose of this study is to see if it is safe and effective to give Viracept to AIDS patients who are being treated for MAC.

Condition	Treatment or Intervention	Phase
Mycobacterium avium-intracellulare Infection HIV Infections	Drug: Nelfinavir mesylate	Phase II

Ages Eligible for Study:  13 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria

Patients must have:

• HIV infection
• New diagnosis of MAC bacteremia and < 7 days of therapy. Prior Medication: Allowed: Patients no more than 7 days of therapy for MAC disease.

Exclusion Criteria

Prior Medication: Excluded: Prior therapy (or less than 2 weeks) with protease inhibitors other than saquinavir.

California
      Harbor UCLA Med Ctr, Torrance,  California,  90502,  United States
      Univ of California / San Diego Treatment Ctr, San Diego,  California,  92103,  United States
Illinois
      Rush Presbyterian - Saint Luke's Med Ctr, Chicago,  Illinois,  60612,  United States
Massachusetts
      Boston VA Med Ctr / 151, Boston,  Massachusetts,  02730,  United States
Texas
      Baylor Univ, Houston,  Texas,  77009,  United States

Study ID Numbers:  259C; Study 518; AG1343-518
Record last reviewed:  May 1999
Last Updated:  October 13, 2004
Record first received:  November 2, 1999
ClinicalTrials.gov Identifier:  NCT00002170
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08